Construction begins on Novartis’ RLT centre in Texas, US
The site is expected to be operational in 2028, adding new roles in advanced manufacturing and bioengineering.
Drug Development
Angelini Pharma to acquire Catalyst Pharmaceuticals for equity value of $4.1bn
Daiichi Sankyo and Waiv partner for ADC biomarkers
Halozyme and Oruka sign agreement for Hypercon technology
Citius raises $36.5m for Lymphir commercialisation
MSD concludes Terns acquisition to expand CML pipeline
Lannett, Lanexa Biologics and Sunshine Lake secure FDA approval for Langlara
Latus Bio secures $97m in funding to boost gene therapy access
